DOI: https://doi.org/10.18370/2309-4117.2016.32.39-44

Epidemiology of HPV infection in Ukraine

А. А. Суханова, І. В. Сідорова, Г. І. Сиротинська, О. А. Бурка

Abstract


The article presents data on the prevalence of humanpapilloma virus (HPV) in Ukraine on the basis of studies of more than 40 000 women of different ages, surveyed in a medical laboratory DILA for the period from 2014 to 2016. Researchers was studied the features of the structure of identification of high risk genotypes of HPV with mild, moderate and severe degree of cervical intraepithelial neoplasia (CIN).

Among all surveyed the number of women with HPV was 34%, the majority of which (65%) were infected with high risk HPV genotypes, and in 90% of cases it was mixed infection.

The structure of the detection of various high risk HPV genotypes in Ukraine is: 16th genotype – 23%, 53th genotype – 16%, 31th genotype – 14%, 33th genotype – 11%, 66th genotype – 11%, 68th genotype – 11%. The greatest proportion of HPV-infected women had an young age (less than 20 years and 20–29 years). It was also found an interesting pattern: then the more severe was the degree of damage to the epithelium, the lower was range of detection of genotypes. If in CIN I were recorded more than 11 kinds of genotypes, and in CIN II – up to 10, and in CIN III – only 3 genotypes. Moreover, the number of cases of mixed infections was reduced with increasing severity of intraepithelial lesions.

Regardless of the severity of intraepithelial lesions the largest share of infected with human papilloma virus Ukrainian women accounted for 16th genotype: 24% with CIN I, 61% – with CIN II, and 70% – with CIN III. Further, among the most common genotypes were 31th, 33th and 18th. Thus, we can assume that in Ukraine the 16th, 31th, 33th and 18th genotypes associated with various degrees of CIN, i.e. women which is infected with these genotypes make up a high-risk group.


Keywords


human papillomavirus (HPV); HPV infection; cervical intraepithelial lesions; Pap test liquid-based cytology

References


World Health Organization. Human papilloma virus (HPV) and cervical cancer. WHO Bulletin number 380 (2015).

Kotaniemi-Talonen, L., Leinonen, M., Hakama, M., et al. “Rate of cervical cancer, severe intraepithelial neoplasia, and adenocarcinoma in situ in primary HPV DNA screening with cytology triage: randomised study within organised screening programme.” BMJ (2010).

Canadian Task Force on Preventive Health Care. Recommendations on screening for cervical cancer. Guidelines (2013).

American Society for Colposcopy and Cervical Pathology. “Use of primary high-risk human papillomavirus testing for cervical cancer screening: interim clinical guidance.” Journal of Lower Genital Tract Disease 19.2 (2015).

Giubilato, P., Carozzi, F., Maina, G., et al; The Italian cervical cancer screening survey group. “Extension of organized cervical cancer screening programmes in Italy and their process indicators, 2011–2012 activity.” Epidemiol Prev 39.3 Suppl. 1 (2015): 1–125.

International Agency for Research on Cancer. European guidelines for quality assurance in cervical cancer screening (2008).

Cutts, T., Franceschi, S., Goldie, S., et al. “Human papillomavirus and HPV vaccines: a review.” Bulletin of the WHO 85.9 (2007).

Nazarova, N.M., Prilepskaya, V.N., Sulamanidze, L.A., et al. “Human papillomavirus infection: incidence, diagnosis and treatment (the literature review).” The attending doctor 11 (2013).

Coscia, M.F., Monno, R., Ballini, A., et al. “Human papilloma virus (HPV) genotypes prevalence in a region of South Italy (Apulia).” Ann Ist Super Sanita 51.3 (2015): 248–51.

Vorobyova, L.I., Neimark, S.L., Baksheev, S.N. “Certain aspects of the prevalence of HPV infection among patients who applied to the antenatal clinic. The composition of the high risk groups. Combination with other infectious agents in the associate.” Materials of the conference in Ternopol, Ukraine (2003).

Sukhanova, A.A., Sirotinskaya, G.I., Shalko, M.N., et al. “Features of detection of HPV infection in Ukraine.” Reproductive Endocrinology 4.18 (2014).

Sjoeborga, K.D., Trope, A., Lie, A.K., et al. “HPV genotype distribution according to severity of cervical neoplasia.” Gynecologic Oncology 118 (2010): 29–34.

Halfon, P., Lindemann, M.L., Raimondo, A., et al. “HPV genotype distribution according to severity of cervical neoplasia using the digene HPV genotyping LQ test.” Arch Virol 158.6 (2013): 1143–9.

Cornall, A.M., Poljak, M., Garland, S.M., et al. “Anyplex II HPV28 detection and Anyplex II HPV HR detection assays are highly concordant with other commercial assays for detection of high-risk HPV genotypes in women with high grade cervical abnormalities.” Eur J Clin Microbiol Infect (2016).


GOST Style Citations


1. Всесвітня організація з охорони здоров’я. Вірус папіломи людини (ВПЛ) та рак шийки матки. ВООЗ: Інформаційний бюлетень № 380 (2015).

2. Kotaniemi-Talonen, L., Leinonen, M., Hakama, M., et al. “Rate of cervical cancer, severe intraepithelial neoplasia, and adenocarcinoma in situ in primary HPV DNA screening with cytology triage: randomised study within organised screening programme.” BMJ (2010).

3. Canadian Task Force on Preventive Health Care.  Recommendations on screening for cervical cancer. Guidelines (2013).

4. American Society for Colposcopy and Cervical Pathology. “Use of primary high-risk human papillomavirus testing for cervical cancer screening: interim clinical guidance.” Journal of Lower Genital Tract Disease 19.2 (2015).

5. Giubilato, P., Carozzi, F., Maina, G., et al; The Italian cervical cancer screening survey group. “Extension of organized cervical cancer screening programmes in Italy and their process indicators, 2011–2012 activity.” Epidemiol Prev 39.3 Suppl. 1 (2015): 1–125.

6. International Agency for Research on Cancer. European guidelines for quality assurance in cervical cancer screening (2008).

7. Cutts, T., Franceschi, S., Goldie, S., et al. “Human papillomavirus and HPV vaccines: a review.” Bulletin of the WHO 85.9 (2007).

8. Назарова, Н.М. Папилломавирусная инфекция: распространенность, диагностика и лечение (обзор литературы) / Н.М. Назарова, В.Н. Прилепская, Л.А. Суламанидзе и др. // Лечащий врач. – 2013. – № 11.

9. Coscia, M.F., Monno, R., Ballini, A., et al. “Human papilloma virus (HPV) genotypes prevalence in a region of South Italy (Apulia).” Ann Ist Super Sanita 51.3 (2015): 248–51.

10. Воробьева, Л.И. Отдельные аспекты распространенности папилломавирусной инфекции среди пациенток, обратившихся в женскую консультацию. Состав высокоонкогенной группы. Сочетание с другими инфекционными агентами в ассоциате / Л.И. Воробьева, С.Л. Неймарк, С.Н. Бакшеев // Материалы конференции в

г. Тернополь. – 2003.

11. Суханова, А.А. Особенности выявления папилломавирусной инфекции в Украине / А.А. Суханова, Г.И. Сиротинская, М.Н. Шалько и др. // Репродуктивная эндокринология. – 2014. – № 4 (18).

12. Sjoeborga, K.D., Trope, A., Lie, A.K., et al. “HPV genotype distribution according to severity of cervical neoplasia.” Gynecologic Oncology 118 (2010): 29–34.

13. Halfon, P., Lindemann, M.L., Raimondo, A., et al. “HPV genotype distribution according to severity of cervical neoplasia using the digene HPV genotyping LQ test.” Arch Virol 158.6 (2013): 1143–9.

14. Cornall, A.M., Poljak, M., Garland, S.M., et al. “Anyplex II HPV28 detection and Anyplex II HPV HR detection assays are highly concordant with other commercial assays for detection of high-risk HPV genotypes in women with high grade cervical abnormalities.” Eur J Clin Microbiol Infect (2016).   





Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.

ISSN 2411-1295 (Online), ISSN 2309-4117 (Print)